Rodwell L T, Anderson S D, Du Toit J, Seale J P
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1149-55. doi: 10.1164/ajrccm/146.5_Pt_1.1149.
We studied 16 asthmatic subjects sensitive to changes in airway osmolarity to determine whether nedocromil sodium has any effect on airway narrowing caused by hypertonic saline challenges. Nedocromil sodium (10 mg) or its vehicle was inhaled 10 min before a challenge with ultrasonically nebulized 4.5% NaCl. FEV1 was measured before challenge and 1 min after each challenge period of 0.5, 1, 2, 4, 8, 8 and 8 min. The challenge was stopped when there was a 20% fall in FEV1 from baseline or after the final challenge period. We measured airway sensitivity, that is, the provoking dose of 4.5% NaCl required to induce a 20% reduction in FEV1 (PD20FEV1) and calculated the fold difference in PD20FEV1 after the intervention. After inhaling nedocromil sodium there was a 3.95-fold improvement in PD20 (p < 0.001) when compared with the vehicle day. After pretreatment with nedocromil sodium two of the 16 subjects were completely protected against 4.5% NaCl challenge, and six developed a plateau in their response. We conclude that nedocromil sodium is effective in reducing airway narrowing in response to 4.5% NaCl challenge in asthmatic subjects, and it appears to be unique in its ability to produce a plateau in response to acute administration of a drug before a bronchial challenge.
我们研究了16名对气道渗透压变化敏感的哮喘患者,以确定奈多罗米钠对高渗盐水激发试验引起的气道狭窄是否有任何影响。在超声雾化吸入4.5%氯化钠激发试验前10分钟,吸入奈多罗米钠(10毫克)或其赋形剂。在激发试验前以及在0.5、1、2、4、8、8和8分钟的每个激发试验期后1分钟测量第一秒用力呼气容积(FEV1)。当FEV1较基线下降20%或在最后一个激发试验期后,停止激发试验。我们测量了气道敏感性,即诱导FEV1降低20%所需的4.5%氯化钠激发剂量(PD20FEV1),并计算干预后PD20FEV1的倍数差异。与使用赋形剂当天相比,吸入奈多罗米钠后,PD20有3.95倍的改善(p<0.001)。在使用奈多罗米钠预处理后,16名受试者中有2名对4.5%氯化钠激发试验完全有保护作用,6名受试者的反应出现平台期。我们得出结论,奈多罗米钠可有效减轻哮喘患者对4.5%氯化钠激发试验的气道狭窄,并且在支气管激发试验前急性给药时,它产生反应平台期的能力似乎是独特的。